....
Press

First vaccinee enrolled

First vaccinee enrolled in a large phase III trial against tuberculosis in a Pan-African setting.

News

Hope for the elderly in the corona pandemic

First participants receive VPM1002 in a late-stage phase III clinical trial in Germany. Read more!

A competent partner at your side

Free first consulting session

We understand how complexe product development is, because we did it ourselves. Let us be a competent partner at your side for a secure route to a successful product.

From Bench to Product

Consulting and services

Speed up your development processes by using our expertise. We offer a comprehensive service portfolio covering all stages of pharmaceutical development.

Next Year

The 13th International VPM Days 2021

On 23 and 24 September 2021, the 13th International VPM Days will take place! Here you can find the report of 2019.

About Vakzine Projekt Management

VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. As a client, you will benefit from the experience of our team in translational project management. This enables you to bring your development projects into clinical trials faster, more cost-effectively and with a higher probability of success.

The company was established in 2002. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.

More about us

News & Press

Press

Press release on VPM's COVID-19 study published in "Neue Presse"

"MHH testet Corona-Impfstoff – besser als Biontech & Co.?" Read more!

Press

First vaccinee enrolled in a large phase III trial against tuberculosis in a Pan-African setting

Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled in a large phase III trial to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. Read more!

Press

Tdap study enters phase III

Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week, which will include adults, adolescents and children to test the safety and immunogenicity of this vaccine. Read more!

Press

30 Million Euro Loan from the EIB for TB

VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa. Read more or Stream the ceremony!

Consulting and services

Speed up your development processes by using our expertise. We offer a comprehensive service portfolio covering all stages of pharmaceutical development.

Our Method

Translational project management from the laboratory bench to clinical development.
powered by webEdition CMS